636 related articles for article (PubMed ID: 31221182)
21. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
22. [Not Available].
Le Bourgeois A
Bull Cancer; 2018 Dec; 105 Suppl 2():S188-S197. PubMed ID: 30686357
[TBL] [Abstract][Full Text] [Related]
23. Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors.
Jindal V; Arora E; Gupta S
Med Oncol; 2018 May; 35(6):87. PubMed ID: 29730801
[TBL] [Abstract][Full Text] [Related]
24. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-armed chimeric antigen receptor-modified T cells for cancer immunotherapy.
Huang Y; Li D; Qin DY; Gou HF; Wei W; Wang YS; Wei YQ; Wang W
Gene Ther; 2018 Jun; 25(3):192-197. PubMed ID: 28820501
[TBL] [Abstract][Full Text] [Related]
26. Obstacles and Coping Strategies of CAR-T Cell Immunotherapy in Solid Tumors.
Miao L; Zhang Z; Ren Z; Tang F; Li Y
Front Immunol; 2021; 12():687822. PubMed ID: 34093592
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor transduced T cells: Tuning up for the next generation.
Schubert ML; Hoffmann JM; Dreger P; Müller-Tidow C; Schmitt M
Int J Cancer; 2018 May; 142(9):1738-1747. PubMed ID: 29119551
[TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
[TBL] [Abstract][Full Text] [Related]
29. Gene modification strategies for next-generation CAR T cells against solid cancers.
Tian Y; Li Y; Shao Y; Zhang Y
J Hematol Oncol; 2020 May; 13(1):54. PubMed ID: 32423475
[TBL] [Abstract][Full Text] [Related]
30. The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
Wang L; Zhang L; Dunmall LC; Wang YY; Fan Z; Cheng Z; Wang Y
Cancer Lett; 2024 Jun; 591():216871. PubMed ID: 38604310
[TBL] [Abstract][Full Text] [Related]
31. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
32. Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Yang QY; Yang JD; Wang YS
Immunol Lett; 2017 Oct; 190():201-205. PubMed ID: 28837818
[TBL] [Abstract][Full Text] [Related]
33. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
34. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
35. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
Bagley SJ; O'Rourke DM
Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
[TBL] [Abstract][Full Text] [Related]
36. CAR-T cell therapy: current limitations and potential strategies.
Sterner RC; Sterner RM
Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
[TBL] [Abstract][Full Text] [Related]
37. Celyad's novel CAR T-cell therapy for solid malignancies.
Lonez C; Hendlisz A; Shaza L; Aftimos P; Vouche M; Donckier V; Machiels JH; Van Den Eynde M; Canon JL; Carrasco J; Odunsi K; Sahebjam S; Rottey S; Braun N; Verma B; Gilham DE; Lehmann FF
Curr Res Transl Med; 2018 May; 66(2):53-56. PubMed ID: 29625833
[TBL] [Abstract][Full Text] [Related]
38. Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions.
Meng X; Jing R; Qian L; Zhou C; Sun J
Front Immunol; 2020; 11():1046. PubMed ID: 32636832
[TBL] [Abstract][Full Text] [Related]
39. Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology.
Watanabe K; Kuramitsu S; Posey AD; June CH
Front Immunol; 2018; 9():2486. PubMed ID: 30416506
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T cells: a novel therapy for solid tumors.
Yu S; Li A; Liu Q; Li T; Yuan X; Han X; Wu K
J Hematol Oncol; 2017 Mar; 10(1):78. PubMed ID: 28356156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]